ArticleTrials2026
Mevalonate supplementation to enhance euploid embryo formation in women of advanced maternal age: a study protocol for a randomized controlled trial.
Article in Trials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05788822 (A Single-center Randomized Controlled Trial on Mevalproic Acid Improving Oocyte Quality and Embryo Development in Elderly Infertile Patients), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Single-center Randomized Controlled Trial on Mevalproic Acid Improving Oocyte Quality and Embryo Development in Elderly Infertile Patients
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundOocyte aneuploidy is a major cause of pregnancy failure in women of advanced maternal age (AMA), and current assisted reproductive technologies offer limited effective strategies to prevent age-related decline in oocyte quality. The mevalonate (MVA) pathway in granulosa cells has recently been implicated in supporting meiotic maturation, but its therapeutic potential in humans remains unclear. This randomized controlled trial is designed to evaluate the effects of MVA supplementation on oocyte competence in women of AMA undergoing preimplantation genetic testing for aneuploidy (PGT-A).
methodsThe study will be conducted as a single-center, prospective, randomized controlled trial. A total of 128 infertile women aged 38-42 years undergoing PGT-A will be enrolled and randomized to either the MVA supplementation group or the control group. Cumulus-oocyte complexes retrieved from each cycle will be allocated according to the randomization protocol, with an estimated 150 cycles analyzed. The primary outcome is the euploidy blastocyst rate, while the secondary outcomes are the clinical pregnancy rate and live birth rate following frozen embryo transfer (FET). DISCUSSION: This trial is expected to evaluate the effects of MVA supplementation on euploidy blastocyst rate and clinical pregnancy outcomes in women of AMA undergoing PGT-A. These findings may provide valuable insights into the potential application of MVA supplementation as an adjunct treatment for infertility in this population.
trial registrationClinicalTrials.gov NCT05788822. Registered in March 2023.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.